[1] Leung K, Lau EHY, Wong CKH, Leung GM, Wu JT. Estimating the transmission dynamics of SARS-CoV-2 Omicron BF.7 in Beijing after adjustment of the zero-COVID policy in November-December 2022. Nat Med 2023;29(3):579 − 82. http://dx.doi.org/10.1038/s41591-023-02212-y.
[2] Diani S, Leonardi E, Cavezzi A, Ferrari S, Iacono O, Limoli A, et al. SARS-CoV-2-the role of natural immunity: a narrative review. J Clin Med 2022;11(21):6272.
[3] Wu NN, Joyal-Desmarais K, Ribeiro PAB, Vieira AM, Stojanovic J, Sanuade C, et al. Long-term effectiveness of COVID-19 vaccines against infections, hospitalisations, and mortality in adults: findings from a rapid living systematic evidence synthesis and meta-analysis up to December, 2022. Lancet Respir Med 2023;11(5):439 − 52.
[4] Tan CY, Chiew CJ, Pang D, Lee VJ, Ong B, Lye DC, et al. Protective immunity of SARS-CoV-2 infection and vaccines against medically attended symptomatic Omicron BA. 4, BA.5, and XBB reinfections in Singapore: a national cohort study. Lancet Infect Dis 2023;23(7):799 − 805.
[5] Chemaitelly H, Tang P, Coyle P, Yassine HM, Al-Khatib HA, Smatti MK, et al. Protection against reinfection with the Omicron BA. 2.75 subvariant. N Engl J Med 2023;388(7):665 − 7.
[6] Chen XS, Xu YL, Xie Y, Song WL, Hu Y, Yisimayi A, et al. Protective effect of plasma neutralization from prior SARS-CoV-2 Omicron infection against BA. 5 subvariant symptomatic reinfection. Lancet Reg Health West Pac 2023;33:100758.
[7] Tamandjou C, Auvigne V, Schaeffer J, Vaux S, du Châtelet IP. Effectiveness of second booster compared to first booster and protection conferred by previous SARS-CoV-2 infection against symptomatic Omicron BA. 2 and BA.4/5 in France. Vaccine 2023;41(17):2754 − 60.
[8] Andeweg SP, de Gier B, Vennema H, van Walle I, van Maarseveen N, Kusters NE, et al. Higher risk of SARS-CoV-2 Omicron BA.4/5 infection than of BA.2 infection after previous BA.1 infection, the Netherlands, 2 May to 24 July 2022. Euro Surveill 2023;28(7):2200724. http://dx.doi.org/10.2807/1560-7917.ES.2023.28.7.2200724.
[9] Wei J, Stoesser N, Matthews PC, Khera T, Gethings O, Diamond I, et al. Risk of SARS-CoV-2 reinfection during multiple Omicron variant waves in the UK general population. Nat Commun 2024;15(1):1008.
[10] Kimura I, Yamasoba D, Tamura T, Nao N, Suzuki T, Oda Y, et al. Virological characteristics of the SARS-CoV-2 Omicron BA. 2 subvariants, including BA.4 and BA.5. Cell 2022;185(21):3992 − 4007.e16.